Foundational LCD, to be effective May 14, 2023, incorporates key feedback to 2022 draft, including updated guidelines recommending non-endoscopic biomarker testing Lucid positioned to submit EsoGuard ...
(RTTNews) - Celularity Inc. (CELU) CEO and Chairman Robert Hariri said that its Biovance and Biovance 3L products will continute to be eligible for medicare coverage under the recent withdrawal of ...
Organogenesis (ORGO) and MiMedx (MDXG) traded lower on Friday after the Centers for Medicare & Medicaid Services (CMS) announced the withdrawal of final Local Coverage Determinations (LCDs) related to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results